The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression

Pharmacopsychiatry

Volumn 38, Issue 3, 2005, Pages 139-143

  Linka, Thomas ^a   Muller B W ^a   Bender, S ^a   Sartory, G ^b   Gastpar, M ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF WUPPERTAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; REBOXETINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; ELECTROPHYSIOLOGY; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; LOUDNESS; MAJOR DEPRESSION; MALE; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE;

ACOUSTIC STIMULATION; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTRODES; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PREDICTIVE VALUE OF TESTS; STATISTICS; TIME FACTORS; TREATMENT OUTCOME;

EID: 22044443910     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-864126     Document Type: Article

References (27)

1. Beauducel A, Debener S, Brocke B, Kayser J. On the Reliability of Augmenting/Reducing. J Psychophysiol 2000; 14(4): 226-240
2. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571
3. Brocke B, Beauducel A, John R, Debener S, Heilemann H. Sensation seeking and affective disorders: characteristics in the intensity dependence of acoustic evoked potentials. Neuropsychobiology 2000; 41: 24-30
4. Buchsbaum M, Silverman J. Stimulus intensity control and the cortical evoked response. Psychosom Med 1968; 30: 12-22
5. Croft RJ, Klugman A, Baldeweg T, Gruzelier JH. Electrophysiological evidence of serotonergic impairment in long-term MDMA ("ecstasy") users. Am J Psychiatry 2001; 158: 1687-1692
6. Gallinat J, Bottlender R, Juckel G, Munke-Puchner A, Stotz G, Kuss HJ, Mavrogiorgou P, Hegerl U. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl) 2000; 148: 404-411
7. Gallinat J, Senkowski D, Wernicke C, Juckel G, Becker I, Sander T, Smolka M, Hegerl U, Rommelspacher H, Winterer G, Herrmann WM. Allelic variants of the functional promoter polymorphism of the human serotonin transporter gene is associated with auditory cortical stimulus processing. Neuropsychopharmacology 2003; 28: 530-532
8. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
9. Hegerl U, Bottlender R, Gallinat J, Kuss HJ, Ackenheil M, Moller HJ. The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci 1998; 248: 96-103
10. Hetzel G, Moeller O, Erfurth A, Michael N, Rothermundt M, Arolt V, Evers S. The impact of the selective monoamine reuptake inhibitors reboxetine and citalopram on visually-evoked event-related potentials in depressed patients. Pharmacopsychiatry 2004; 37: 200-205
11. Juckel G, Hegerl U, Molnar M, Csepe V, Karmos G. Auditory evoked potentials reflect serotonergic neuronal activity - a study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology 1999; 21: 710-716
12. Juckel G, Mavrogiorgou P, Bredemeier S, Gallinat J, Frodl T, Schulz C, Moller HJ, Hegerl U. Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders - a retrospective study. Pharmacopsychiatry 2004; 37: 46-51
13. Kuenzel HE, Murck H, Held K, Ziegenbein M, Steiger A. Reboxetine induces similar sleep-EEC changes like SSRI's in patients with depression. Pharmacopsychiatry 2004; 37: 193-195
14. Linka T, Müller BW, Bender S, Sartory G. The intensity dependence of the auditory evoked N1 component as a predictor to Citalopram treatment in patients with major depression. Neuroscience Letters, 2004: in press
15. Mulert C, Jager L, Pogarell O, Bussfeld P, Schmitt R, Juckel G, Hegerl U. Simultaneous ERP and event-related fMRI: focus on the time course of brain activity in target detection. Methods Find Exp Clin Pharmacol 2002; 24 Suppl D: 17-20
16. (NIMH) NIoMH. CGI. Clinical global impressions. In: Bonato R, ed. Manual for the EDCEU assessment battery, 2nd edition. Vol. 12 (R. Bonato, ed) NIMH, Chevy Chase: 1976
17. Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 2004; 65 Suppl 4: 5-10
18. Paige SR, Fitzpatrick DF, Kline JP, Balogh SE, Hendricks SE. Event-related potential amplitude/intensity slopes predict response to antidepressants. Neuropsychobiology 1994; 30: 197-201
19. Proietti-Cecchini A, Afra J, Schoenen J. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia 1997; 17: 849-854; discussion 799
20. Quednow BB, Kuhn KU, Stelzenmueller R, Hoenig K, Maier W, Wagner M. Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression. Psychopharmacology (Berl), 2004
21. Semlitsch HV, Anderer P, Schuster P, Presslich O. A solution for reliable and valid reduction of ocular artifacts, applied to the P300 ERP. Psychophysiology 1986; 23: 695-703
22. Strobel A, Debener S, Schmidt D, Hunnerkopf R, Lesch KP, Brocke B. Allelic variation in serotonin transporter function associated with the intensity dependence of the auditory evoked potential. Am J Med Genet 2003; 118B: 41-47
23. Tuchtenhagen F, Daumann J, Norra C, Gobbele R, Becker S, Pelz S, Sass H, Buchner H, Gouzoulis-Mayfrank E. High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology 2000; 22: 608-617
24. von Knorring L, Johansson F. Changes in the augmenter-reducer tendency and in pain measures as a result of treatment with a serotonin-reuptake inhibitor - zimelidine. Neuropsychobiology 1980; 6: 313-318
25. von Knorring L, Perris C. Biochemistry of the augmenting-reducing response in visual evoked potentials. Neuropsychobiology 1981; 7: 1-8
26. Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of auditory evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic neurotransmission? Neurology 1996; 46: 1404-1409
27. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004; 161: 1575-1580